Effect of Empagliflozin on Body Composition and Ketones

Last updated: August 10, 2023
Sponsor: Seoul National University Bundang Hospital
Overall Status: Active - Recruiting

Phase

4

Condition

Diabetes Prevention

Diabetes And Hypertension

Treatment

Empagliflozin 10 MG

Hypoglycemics Oral

Clinical Study ID

NCT03877406
B-1507/307-007
  • Ages > 20
  • All Genders

Study Summary

The purpose of this study is to evaluate changes of body composition induced by Sodium-glucose cotransporter-2 (SGLT2) inhibitor and its metabolic consequence in Korean type 2 diabetes (T2D).

Eligibility Criteria

Inclusion

Inclusion Criteria: Patients with type 2 diabetes Age: 20-79 years BMI ≥ 20 kg/m2 eGFR ≥ 45

Exclusion

Exclusion Criteria: Patients with type 1 diabetes Secondary diabetes due to Cushing diseases, acromegalyInsulin user BMI < 20 kg/m2 eGFR < 45 Malignancy

Study Design

Total Participants: 200
Treatment Group(s): 2
Primary Treatment: Empagliflozin 10 MG
Phase: 4
Study Start date:
August 01, 2018
Estimated Completion Date:
December 31, 2023

Study Description

Sodium-glucose cotransporter-2 (SGLT2) inhibitor increases urinary excretion of glucose, promoting glycemic control and weight loss. However, it is unclear whether weight loss is attributed to decrease in fat components and associated with favorable changes in metabolic profile. The purpose of this study is to evaluate changes of body composition induced by SGLT2 inhibitor and its metabolic consequence in Korean type 2 diabetes (T2D).

Connect with a study center

  • Seoul National University Bundang Hospital

    Seongnam, Gyeonggi 463-707
    Korea, Republic of

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.